Eton Pharmaceuticals, Inc. Long-Term Debt
Eton Pharmaceuticals, Inc. (ETON) had Long-Term Debt of $19.08 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2026-08-13
- 2026-06-30: Long-term Debt, Excluding Current Maturities $19.08M.
- 2026-03-31: Long-term Debt, Excluding Current Maturities $18.94M.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $21.77M.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $27.59M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2026-06-30 | $19.08M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $18.94M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $21.77M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $27.59M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $27.41M 10-Q · filed 2025-08-07 |
| 2024-12-31 | $29.81M 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |